IQVIA Target Raised to $300 by HSBC, Institutional Interest Grows

HSBC raised its price target for IQVIA Holdings Inc. to $300 from $280. The investment bank maintained its Buy rating on the stock.

Institutional investors are increasing their positions in the medical research company. UBS AM boosted its IQVIA holdings by 9.0% during the second quarter. This increase brings UBS AM’s total ownership to nearly 1% of the company. Corient Private Wealth LP also initiated a new position in the firm.